5.88204538325745E-05 0.000640489386175898 0.00115680225870556 0.00155547422357008 0.0012809787723518 0.0012809787723518 0.0012809787723518 0.0012809787723518
Sign Up Today X
Thanks for submitting the form.
Stockreport

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: GlobeNewswire
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices in other developed countries; prices for future medicines in the U.S. will be aligned with prices set in that defined group of other countries Praluent® (alirocumab), an important cardiovascular medicine, will be available for direct patient purchase through TrumpRx.gov Regeneron will continue its large investment in domestic R&D and manufacturing capacity TARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an agreement with the U.S. government to help lower prices of several of its current and future life-changing medicines and offer an important new medicine for free in the U.S., ensuring American patients gain broader access to innovative treatments. Regeneron leaders and co-founders Leonard Schleif [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: GlobeNewswire
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices in other developed countries; prices for future medicines in the U.S. will be aligned with prices set in that defined group of other countries Praluent® (alirocumab), an important cardiovascular medicine, will be available for direct patient purchase through TrumpRx.gov Regeneron will continue its large investment in domestic R&D and manufacturing capacity TARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an agreement with the U.S. government to help lower prices of several of its current and future life-changing medicines and offer an important new medicine for free in the U.S., ensuring American patients gain broader access to innovative treatments. Regeneron leaders and co-founders Leonard Schleif [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS